HYDERABAD Feb 25 (Reuters) - Medical device maker Medtronic (MDT.N), opens new tab is looking at options to modify its global manufacturing footprint as part of efforts to mitigate any impact of U ...

Medtronic's BrainSense aDBS personalizes Parkinson's therapy in real-time, minimizing manual adjustments for better symptom control. BrainSense Electrode Identifier speeds up initial DBS ...

Northampton General Hospital hoped up to 28 people would benefit from the Medtronic Micra devices over the next year. The pacemaker weighs under two grams (0.1oz) and is administered to cardiac ...

Medtronic is a diversified medical device maker with a global footprint. Its reliably growing dividend has helped fuel its stock performance for decades. Its shares are reasonably valued for the ...

A clinician uses Medtronic's pulsed field ablation system for treating atrial fibrillation last month. On Tuesday, Medtronic reported adjusted quarterly net profit of $1.8 billion on $8.3 billion ...

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success was offset by weaker sales from its medical-surgical business.

Medtronic missed Wall Street's fiscal 2025 Q3 revenue estimate but beat earnings expectations. The company's revenue miss appears to be primarily related to a temporary change in distributor ...

Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release ...

Medtronic (NYSE:MDT) traded lower in pre-market hours Tuesday, down 4.54% to $88.60 as of 08:20 AM ET, despite reaffirming its full-year guidance alongside its Q3 FY25 results. The MedTech giant ...

Medtronic brought in revenues of $8.3bn for the quarter, up 2.5% from the same period in 2024. Image credit: Shutterstock / JHVEPhoto. Medtronic posted a strong profit for Q3 of fiscal year 2025, ...

It is approved for anyone 18 years and older who does not use insulin. Sensors can be worn up to 15 days. Medtronic's Guardian Connect CGM, which is approved for people with diabetes ages 14 and up, ...